3D Systems Corporation delivered a mixed financial performance for the fourth quarter, surpassing its own revenue expectations while simultaneously projecting a challenging start to the new year. The additive manufacturing specialist reported quarterly revenue of $106.3 million, a figure that represents a 16% increase from the third quarter and exceeded the company's November guidance for 8% to 10% sequential growth.
Annual Results and Diverging Segments
Despite the quarterly beat, the company's full-year revenue for 2025 declined by 12% to $386.9 million, down from $440.1 million in the prior year. A deeper look at the quarterly results reveals a stark divergence between its business segments. Revenue from the Healthcare Solutions unit, which includes medical and dental applications, surged 25% year-over-year to $50.5 million. Conversely, the Industrial Solutions division, which serves broader manufacturing and prototyping markets, contracted by 21% to $55.8 million.
On a profitability basis, the company reported GAAP net income of $29.9 million for the year, a positive swing attributed largely to gains from asset sales, cost reduction initiatives, and lower impairment charges. However, a more critical operational metric, adjusted EBITDA, remained deep in negative territory at a loss of $45.4 million for the year, indicating ongoing core business challenges.
Management Commentary and Strategic Focus
Chief Executive Jeffrey Graves stated the quarter "exceeded our expectations," highlighting med tech, dental, and aerospace as sectors that are "rapidly adopting 3D printing." These areas are central to the company's current product cycle and long-term strategy. The firm noted a 16% annual increase in aerospace and defense revenue for 2025 and is targeting 20% growth in that segment for 2026.
Interim CFO Phyllis Nordstrom emphasized the company's continued intense focus on reducing overall spending, detailing that approximately $55 million in annualized savings have been secured for 2025. A significant financial restructuring was also completed, as a debt-for-equity swap pushed the majority of the company's debt, originally maturing in late 2026, out to 2030. This leaves only $3.9 million due in Q4 2026, with $92 million now scheduled for 2030.
Concerning Guidance and Financial Metrics
The outlook for the first quarter of 2026 casts a shadow over the sequential progress. Management guided for revenue between $91 million and $94 million, indicating a anticipated decline. Furthermore, adjusted EBITDA is projected to remain negative, in a range of negative $5 million to negative $3 million, which would be worse than the prior quarter's result. The company's previous goal of achieving break-even or better adjusted EBITDA by the end of 2025 has been abandoned.
Other financial metrics also showed pressure. The gross margin slipped to 30.8% in the quarter. Perhaps more alarmingly, cash and cash equivalents fell sharply to $95.6 million, down from $171.3 million a year earlier, reflecting the costs associated with the ongoing turnaround and restructuring.
Market Context and Competitive Landscape
The report paints a mixed picture for the broader additive manufacturing sector. Key rivals like Stratasys and Materialise are also pivoting toward high-value production and healthcare specialties. Last week, Stratasys disclosed that manufacturing accounted for 37.5% of its revenue but warned that tariffs and currency movements could reduce 2026 earnings by roughly $17 million. Meanwhile, Materialise reported its medical division grew 16.3% in the fourth quarter.
3D Systems' performance underscores the industry's shift away from traditional prototyping toward applications in sectors with deeper R&D and capital budgets, such as healthcare and aerospace. The company's future success hinges on its ability to convert recent printer shipments into recurring, high-margin sales of materials and services once those systems are deployed at customer sites.
The path forward remains uncertain. While the debt restructuring provides a longer runway, the weak Q1 forecast, dwindling cash reserves, and persistent adjusted EBITDA losses highlight the significant hurdles that remain in the company's recovery narrative. Investors and industry watchers will be closely monitoring whether the strategic focus on healthcare and aerospace can generate sustainable profitability in the face of ongoing softness in industrial markets.